A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults

This publication has 22 references indexed in Scilit:

• Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial
  The Lancet, 2005
• Malaria vaccines in development
  Emerging Drugs, 2005
• WHO estimates of the causes of death in children
  The Lancet, 2005
• Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial
  The Lancet, 2004
• Antimalarial combinations
  The Lancet, 2004
• Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
  The Lancet, 2001
• Efficacy of Recombinant Circumsporozoite Protein Vaccine Regimens against ExperimentalPlasmodium falciparumMalaria
  The Journal of Infectious Diseases, 2001
• The economic burden of malaria
  The American Journal of Tropical Medicine and Hygiene, 2001
• Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.
  The Journal of Infectious Diseases, 1998
• A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalaria
  New England Journal of Medicine, 1997